19th July 2021
Drug Development Company Bridge Therapeutics Names David H. Bergstrom, Ph.D. as Chief Executive Officer
Birmingham, AL – July 19 2021 – Bridge Therapeutics Inc. (Bridge) has promoted David H. Bergstrom, Ph.D. to the position of interim Chief Executive Officer.
Dr. Bergstrom has more than 30 years of new product development and commercialization experience in the pharmaceutical industry. He has overseen and been intimately involved in moving new products from the research phase to eventual successful commercial production and launch across numerous therapeutic areas and dosage form delivery technologies. Dave has experience in large, small, semi-virtual and contract development companies. He earned his undergraduate degree in Pharmacy and graduate degrees in Pharmaceutics and Pharmaceutical Chemistry. Dave has been intimately involved in developing Bridge’s lead product candidate, with an emphasis on Manufacturing, CRO and CDMO management, Project Management and Regulatory work and FDA interaction.
The company’s lead product, BT-219, or Bunalz, is a clinical stage investigational new drug applying Catalent’s Zydis® ODT (orally disintegrating tablet) delivery technology of buprenorphine and naloxone, which are the active ingredients in Suboxone®. Catalent’s proprietary Zydis® technology is a unique, freeze-dried, sublingual delivery system.
“On behalf of the entire board, I want to congratulate Dave on his new role as interim CEO. I also want to thank him for his contribution to the company and for his leadership during the company’s early development years. Since joining Bridge as COO in 2018 Dave has been instrumental in the growth and development of Bridge Therapeutics and the drug products in our pipeline. As an industry veteran with a deep understanding of how to take new products from inception to approval, I know Dave will continue providing the leadership necessary to execute the company’s strategy”.
Greg Sullivan, MD, Chairman of the Board
About Bridge Therapeutics
Bridge Therapeutics is an innovative, late-development-stage specialty pharmaceutical company pursuing FDA approvals of its investigational drugs BT-219 and BT-205. BT-219 is a state-of-the-art formulation of Buprenorphine and Naloxone for the treatment of opioid dependence. BT-219 utilizes Catalent’s Zydis® Orally Disintegrating Tablet (ODT) technology. Also under development is BT-205, a patented (U.S. Patent #8410092) drug combination for the treatment of chronic pain in opioid-experienced patients. BT-205 combines two chronic pain drugs — the partial-agonist opioid buprenorphine and the non-steroidal anti-inflammatory drug (NSAID) meloxicam. Bridge Therapeutics’ goal is to help combat the opioid crisis by making its treatments available for use.